Table 1. Demographics and clinical profile of patients with super-giant HCC.
| Median age, years (range) | 65.5 (55–77) |
| Gender, n (%) | |
| Male | 17 (94.4) |
| Female | 1 (5.6) |
| Risk factors, n (%) | |
| HBV | 7 (38.9) |
| Alcohol and HBV | 2 (11.1) |
| No risk factors | 9 (50.0) |
| Comorbidities, n (%) | |
| Hypertension | 9 (50.0) |
| Diabetes mellitus | 8 (44.4) |
| Hyperlipidemia | 7 (38.9) |
| Stroke | 2 (11.1) |
| Ischemic heart disease | 4 (22.2) |
| Chronic renal disease | 3 (16.7) |
| Pulmonary disease | 2 (11.1) |
| Child-Pugh score, n (%) | |
| A | 17 (94.4) |
| B | 1 (5.6) |
| C | 0 |
| BCLC stage, n (%) | |
| A | 0 |
| B | 14 (77.8) |
| C | 4 (22.2) |
| HKLC stage, n (%) | |
| I, IIa | 0 |
| IIb | 15 (83.3) |
| IIIa | 1 (5.6) |
| IIIb | 2 (11.1) |
| Iva, IVb | 0 |
| Va, Vb | 0 |
| Pre-operative treatment, n (%) | |
| TACE | 1 (5.6)* |
| None | 17 (94.4) |
*
This patient also received portal vein embolization. HBV, hepatitis B virus; BCLC, Barcelona Clinic for Liver Cancer; HKLC, Hong Kong liver cancer; TACE, transarterial chemoembolization.